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Abstract:  Evaluation  of  metabolic  control  of  diabetic  people  has  been  classically 
performed  measuring  glucose  concentrations  in  blood  samples.  Due  to  the  potential 
improvement  it  offers  in  diabetes  care,  continuous  glucose  monitoring  (CGM)  in  the 
subcutaneous tissue is gaining popularity among both patients and physicians. However, 
devices for CGM measure glucose concentration in compartments other than blood, usually 
the interstitial space. This means that CGM need calibration against blood glucose values, 
and the accuracy of the estimation of blood glucose will also depend on the calibration 
algorithm. The complexity of the relationship between glucose dynamics in blood and the 
interstitial space, contrasts with the simplistic approach of calibration algorithms currently 
implemented in commercial CGM devices, translating in suboptimal accuracy. The present 
review will analyze the issue of calibration algorithms for CGM, focusing exclusively on 
the commercially available glucose sensors. 
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1. Introduction 
Following the demonstration of the causal relationship between microvascular complications and 
hyperglycaemia [1,2], monitoring of glycaemic status is considered a cornerstone of diabetes care. 
During the past 40 years, technical advances have allowed for dramatic changes of monitoring of 
metabolic  control.  Before  1975,  routine  patient  monitoring  consisted  of  urine  glucose  and  ketone 
determinations [3]. Typically, physicians monitored occasional laboratory blood glucose determinations 
and reviewed patient home urine testing records. The primary purpose of monitoring was to provide 
information to the patient‘s health care provider to guide changes in therapy to relieve symptoms due 
to hyperglycemia (polyuria, polydipsia and nocturia) rather than to achieve specific glycaemic goals. 
Since 1975, technical advances allowed for radical changes in glucose monitoring. In 1971 the first 
blood glucose monitor for point-of-care use in patients with diabetes was patented in the USA by 
Anton Clemens: the Ames Reflectance Meter. It was based on optical detection of a color change on 
glucose oxidase-based strips, and was succeeded by the Ames Eytone, which became commonplace in 
physicians‘ offices and hospitals. A number of clinical studies, in the late 1970s, demonstrated that the 
technology  improved  metabolic  control  and  was  applicable  for  self-management  of  patients  in 
everyday  life  [4-8].  During  the  1980s,  technology  for  home  glucose  measurement  moved  from 
reflectance devices to electrochemical biosensor-based glucose sensing, the first amperometric glucose 
biosensor being described in 1984 and commercialized in 1987 [9,10]. Due to technical advances and 
to  the  increasing  evidence  of  its  usefulness,  by  the  mid-1980s,  self-monitoring  of  blood  glucose 
(SMBG) had already replaced urine glucose testing as the recommended method of home testing and, 
at  present,  it  is  considered  a  fundamental  part  of  the  management  of  all  patients  with  diabetes, 
especially those who use insulin [11]. 
Parallel  to  the  development  of  SMBG,  progress  with  enzyme  electrodes  in  the  1970s  [12-16] 
allowed  for  the  emergence  of  continuous  glucose  monitoring  (CGM),  and  for  the  subsequent 
development of the first prototypes of glucose-sensor controlled insulin infusion systems, by different 
groups [17-20]. The next two decades saw huge progress in the development of continuous glucose 
sensing. Research focused on the skin as an appropriate candidate for direct glucose measurement. 
Indeed,  the  subcutaneous  tissue  is  easily  accessible  for  sensor  implantation  and  measurement  of 
glucose  in  the  interstitial  fluid,  with  fewer  problems  as  compared  to  the  intravascular  space.  The 
amperometric glucose-sensing technique was refined and this process culminated, in 1999, with the 
development and FDA approval of the CGMS
®, the first commercial CGM device [21]. In the attempt 
to obtain non-invasive CGM, several technologies alternative to electroenzymatic sensors have been 
studied  or  are  under  development:  spectroscopy,  sonophoresis,  polarimetry,  infrared,  fluorescence, 
light-emitting diode, electromagnetic radiant ray and laser [22]. However, to date, direct interstitial 
fluid glucose measurement is the only technique that has been thoroughly tested and is commercially 
available for diabetic people. Devices using this technique are referred to as minimally invasive, and 
operate  with  either  a  subcutaneous  needle-like  sensor,  sensor-based  microdialysis  or  reverse 
iontophoresis. All of them use glucose-oxidase enzyme-based technology and differ in the way the 
interstitial fluid is sampled.  
Evaluation of metabolic control, as well as adjustment of diabetes therapy, has been classically 
performed based on measurement of glucose concentrations in blood samples. However, devices for Sensors 2010, 10                                       
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CGM  measure  glucose  concentration  in  compartments  other  than  blood,  i.e.,  directly  in  the 
subcutaneous interstitial fluid (commercially available devices), or indirectly from changes in specific 
properties of a given tissue (usually the skin: non-invasive methods under development). This means 
that CGM requires calibration against concurrent blood glucose values, thus providing an estimate of 
blood glucose concentration, based on the assumption that glucose concentration in the interstitial fluid 
(or in the skin, in the case of non-invasive methods), is directly related to blood glucose concentration. 
However,  this  is  a  simplification,  and  the  accuracy  of  the  estimation  of  blood  glucose  from  the 
measurement in the interstitial space will depend, among other factors, on the calibration algorithm. 
Indeed,  the  latter  is  a  function  that,  in  some  way,  includes  the  relationship  between  plasma  and 
interstitial glucose. Clearly, the more precise and robust the calibration algorithm, the plasma glucose 
estimates will be more accurate. Unfortunately, however, few studies have systematically investigated 
the  relationship  between  plasma  and  interstitial  glucose  [23-29],  with  heterogeneous  results.  This 
highlights the complexity of such a relationship, which contrasts with the rather simplistic approach of 
calibration algorithms currently implemented in commercial CGM devices, resulting in suboptimal 
accuracy especially under conditions of hypoglycemia [22]. 
The  present  review  will  analyze  the  issue  of  calibration  algorithms  for  CGM.  For  the  sake  of 
brevity, we will focus exclusively on the commercially available glucose sensors. In 2007, the only 
device using the iontophoresis technique, the Glucowatch Biographer (Animas Corp, West Chester, 
PA, USA) was  retired from  the market.  The GlucoDay  (Menarini  Diagnostics, Florence,  Italy), a 
microdialysis device, is intended only for professional use. Therefore, only needle-like subcutaneous 
sensors are available on the market for home CGM. They are summarized in Table 1. 
Table 1. Devices currently available for home continuous glucose monitoring. 
Device  Company  Technique  Real-time 
Associated with 
insulin pump 
CGMS iPro  Medtronic Minimed  Subcutaneous sensor  No  No 
Guardian REAL-Time  Medtronic Minimed  Subcutaneous sensor  Yes  No 
Paradigm REAL-Time  Medtronic Minimed  Subcutaneous sensor  Yes  Yes 
Paradigm Veo  Medtronic Minimed  Subcutaneous sensor  Yes  Yes 
SEVEN  Dexcom Inc.  Subcutaneous sensor  Yes  No 
SEVEN Plus  Dexcom Inc.  Subcutaneous sensor  Yes  No 
Freestyle Navigator  Abbott Inc.  Subcutaneous sensor  Yes  No 
2. Glucose Sensing from the Interstitial Space 
Current commercial glucose sensors are all based on the indirect measurement of glucose from the 
interstitial space through amperometric enzyme electrodes  based on  glucose-oxidase  (GOx). Good 
reviews  of  these  systems,  as  well  as  other  techniques  under  investigation  for  non-invasive 
measurement, can be found elsewhere [30-32].  
The operating principle of amperometric sensors is the measurement of the current flowing from an 
oxidation reaction, at a working electrode, to a reduction reaction, at a counter electrode [33]. To this 
purpose,  a  potential  is  applied  between  the  working  electrode  and  a  reference  electrode.  Three 
electrodes are thus needed (working, counter and reference electrodes), although some sensors use a Sensors 2010, 10                                       
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two-electrode  configuration  (working  and  counter-reference  electrode),  combining  the  counter  and 
reference  electrodes.  Medtronic  and  Abbott  use  three-electrode  configurations.  DexCom  uses  a  
two-electrode configuration. 
In the case of glucose sensing, GOx is immobilized at the working electrode. GOx catalyses the 
oxidation  of  glucose  to  gluconolactone.  To  this  end,  GOx  requires  as  cofactor  Flavin  Adenine 
Dinucleotide (FAD) that will act as electron acceptor reducing to FADH2, according to the following 
reaction [32]: 

Glucose + GOx(FAD)  Gluconolactone + GOx(FADH2)      (1) 
The FAD cofactor (redox active center) is deeply embedded in the GOx molecular structure  [34]. 
This necessitates the use of mediators or other strategies to improve communication between the 
enzyme and the electrode surface ―guiding‖ electrons to the electrode. The natural mediator is the 
couple oxygen/hydrogen peroxide (O2/H2O2), according to the reactions: 

GOx(FADH 2)+O2   GOx(FAD)+H2O2
H2O2  2H
+ O2 2e
-         (2) 
The flavin is re -oxidized in the presence of oxygen, producing hydrogen peroxide. This is 
monitored measuring the current generated after the application of a p otential (around  +0.6 V vs. 
Ag/AgCl)  between  the  working  electrode  and  a  reference  electrode.  This  is  the  method  used,  for 
instance, in the Medtronic and DexCom monitors. 
Two main problems have to be dealt with: 
a)  Other  electro-active  molecules  such  as  uric  acid  and  ascorbic  acid  may  interfere  in  the 
measurement,  depending  on  the  potential  applied.  To  reduce  interference  and  increase 
selectivity to  glucose,  membranes  limiting the access  of these molecules to  the electrode 
surface are included, or electrodes are built in materials requiring a lower potential. 
b)  Glucose concentration is much higher than oxygen concentration. A proper glucose-oxygen 
ratio must be obtained. To this end, membranes are included limiting the transport of glucose 
to the electrode in order to maximize oxygen availability.  
The main differences between the Medtronic and DexCom sensors consist in how these problems 
are tackled. The Medtronic sensor uses a polymer membrane to address the oxygen deficit problem. In 
DexCom sensor a barrier membrane is incorporated to reduce the glucose flow, reducing consequently 
the production of hydrogen peroxide, which may damage the electrode. In this way, more durability  
is gained [32]. 
The Abbott sensor avoids the use of oxygen as a mediator. Instead, a wired enzyme technology is 
used. The GOx active center is ―wired‖ to the electrode by means of osmium-based redox polymers, 
establishing  direct  electrical  communication  [35].  This  allows  a  low  reaction  potential  (−0.2  V), 
reducing the interference of electro-active molecules [33]. 
3. Relationship between Plasma, Capillary and Interstitial Glucose 
Glucose  exchange  across  the  capillary  walls  occurs  by  simple  diffusion  across  a  concentration 
gradient. However, this process is not instantaneous and appears to be influenced by both blood flow Sensors 2010, 10                                       
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and capillary permeability [36,37]. Indeed, recent data demonstrate that the interstitial glucose pool of 
muscle and adipose tissue are part of a compartment which is in relatively slow equilibrium with 
plasma glucose (see Figure 1) [38].  
Figure 1. Compartmental model of glucose transport. 
 
 
The obvious consequence of limited transcapillary exchange of glucose is that any change in plasma 
glucose concentration, as well as in the metabolic rate and glucose uptake by cells, will affect the 
plasma-to-interstitial fluid (ISF) concentration difference [23,24,26,28,39]. The latter is best known as 
physiological lag time between plasma and ISF glucose. The presence of such a lag is widely reported 
and acknowledged. However, a great degree of variation has been observed, with lag times ranging 
from  0  to  45  minutes.  Although  the  majority  of  researchers  in  the  field  put  the  lag  time  into  
the 5–15 minutes range [27,40-46], the huge variability observed is well explained by the complexity 
of the plasma to ISF glucose relationship. Indeed, different experimental conditions, representative of 
different metabolic conditions, are likely to result in different estimations of physiological lag time. As 
an  example,  the  fall  of  glucose  concentration  in  the  interstitium  has  been  shown  to  occur  either  
before [26,28] or after [47,48] that observed in plasma. This may be explained, at least in part, by 
different plasma insulin concentrations reached during the experiments. In fact, in physiology, glucose 
fluxes (i.e., hepatic production and peripheral uptake), are strictly insulin dependent. This means that, 
under low (but relatively high) plasma insulin concentrations, hypoglycemia is only the result of the 
suppression of hepatic glucose production (EGP): in this case, glucose concentration is expected to fall 
sooner  in  plasma  than  in  the  ISF.  On  the  other  hand,  under  high  insulin  concentrations  (such  as 
following prandial insulin administration), hypoglycemia is the result of both hepatic suppression and 
the increase of peripheral uptake of glucose by fat and muscle (GU): this scenario is more complex 
(the so  called ‗push-pull phenomenon‘) and glucose concentration may fall in  ISF sooner than in 
plasma [23,26,28]. Several recent studies that have evaluated the plasma-to-ISF relationship, have used 
correlation analysis to assess the lag time, underlines the small impact of the physiological delay on the 
overall analytical error of CGM monitors as compared to reference methods [27,40-46]. In particular, 
one study specifically argues against the existence of a push-pull phenomenon [46], suggesting that the 
plasma-to-ISF glucose dynamic may be simpler, and the delay of interstitial glucose upon plasma 
glucose change may be smaller, than previously postulated [23,38]. Those studies are largely based on Sensors 2010, 10                                       
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data from clinical trials. However, if the latter are representative of real life for patients with diabetes, 
they  are  not  best  suited  to  describe  physiology.  Indeed,  pooling  of  data  from  uncontrolled  and 
potentially different metabolic conditions may easily mask physiologic phenomena. Another potential 
simplification of the plasma-to-ISF glucose relationship may be due to the use of correlation or curve 
fitting methods (maximum statistical agreement criterion), to assess time lag. Indeed, if these methods 
can estimate the mean delay (which is described as a point estimate) between the two compartments, 
they are based on the assumption that its relationship is linear. However, this may not be true, as 
supported by the finding of different time lags at different rates of change of plasma glucose [41,43] 
and by previous elegant physiologic studies [23], even with independent measurement of ISF glucose 
concentrations  [26].  Hence,  accurate  estimation  of  plasma  glucose  from  measurements  in  the  ISF 
seems to require mathematical models describing the relationship (tissue-specific) between plasma and 
ISF glucose levels, both during steady state and dynamic conditions. However, to make the issue even 
more complex, there is the potential influence of the technique used to sample the ISF on the lag time. 
Indeed, it must be taken into account that insertion of a needle-like sensor, as well as a microdialysis 
fiber or a microperfusion catheter, disrupts the physiologic architecture of the subcutaneous tissue and 
is associated with an inflammatory response [49] and a foreign body reaction, which are specific to the 
materials used [50]. Indeed, the biocompatibility of implantable glucose sensors remains a critical 
issue  in  limiting  CGM  device  longevity  and  functionality,  and  most  functional  loss  of  biosensor 
activity  is  assumed  to  be  caused  by  histological  changes  that  occur  in  the  tissue  surrounding  the 
implant  (inflammatory  reaction  and/or  fibrous  encapsulation)  [50].  The  material-tissue  interaction 
during sensor implantation, the so-called biofouling, is recognized as one of the major factors resulting 
in  unpredictable  and  unexplainable  behaviors  of  implanted  glucose  biosensors.  In  fact,  the 
performance  of  implanted  biosensors  may  greatly  benefit  from  the  use  of  more  biocompatible 
outermost coatings, as recently demonstrated in animal experiments where a hydrogel coating was 
effective in minimizing tissue reactions surrounding implanted minimally invasive needle-type glucose 
biosensors [51]. Improving glucose sensors biocompatibility would rule out the problem of loss of 
sensitivity during the sensor lifetime [52], certainly allowing for better description of the plasma to 
interstitial glucose dynamic. 
Finally, it should be noted that the intra-individual sensor to sensor variability (two identical sensors 
placed  in  the  same  subject  at  the  same  time),  has  been  shown  to  be  greater  than  the  apparent 
physiological lag time [27], potentially hampering our ability to describe physiologic phenomena. This 
underlines the importance of finding calibration strategies which include dynamic models specific to 
each device used for CGM. 
4. Estimating Plasma Glucose from Interstitial Glucose 
4.1. Getting Calibration Points 
Calibration of CGM devices is usually done by means of plasma glucose values obtained with 
glucometers, which measure capillary plasma glucose concentrations. This is reasonable, since self 
monitoring of capillary plasma glucose (SMBG) is the gold standard of glycemic testing in everyday 
life diabetes care. However, it may contribute substantially to the inaccuracy of CGM devices, as has Sensors 2010, 10                                       
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been recently demostrated by Kamath et al., who showed a significant reduction of CGM error when it 
was calibrated against a reference method (venous plasma glucose with the YSI) instead of capillary 
plasma glucose [42]. This is not surprising, since accuracy of SMBG is influenced by several factors 
such as test strip handling, proper glucometer coding and procedural factors (meter cleanliness and 
careless hand washing, the size and placement of the blood sample, etc.), among others (for a detailed 
description see reference [53]). Indeed, accuracy of SMBG has been demonstrated to be technique  
dependent [11], as shown by poorer performance of glucometers among patients as compared with 
technicians  [54].  In  addition,  the  relationship  between  venous,  plasma  and  capillary  blood 
measurements is not fixed, varying with the metabolic status of the patient: if they are similar in the 
fasting  state,  post-prandial  capillary  samples  generally  show  values  higher  than  in  venous  
plasma  [55,56].  To  generate  further  confusion,  some  glucometers  quantify  whole-blood  glucose 
(instead of the recommended plasma glucose), which reads 10%–15% lower than plasma. All these 
explain  why  today‘s  meters  are  capable  of  producing  results  that  meet  established  standards  of 
accuracy  under  controlled  conditions,  but  clinical  studies  demonstrating  consistently  comparable 
performance in the hands of patients are lacking.  
Given the abovementioned issues on calibration with SMBG values, it is not surprising that both the 
quality and the timing of calibration points have been recognized as crucial factors influencing the 
accuracy  of  CGM  readings  [57,58].  However,  the  importance  of  calibrating  during  steady  state 
conditions  (i.e.,  avoiding  calibration  during  rapid  changes  of  plasma  glucose)  has  been  recently 
questioned by some authors, who showed no detrimental effect [42], or even improvement, in CGM 
accuracy following calibration under dynamic conditions  [59], demonstrating that reduction of the 
patients‘  SMBG  technique  related  errors  is  probably  of  greater  effectiveness.  In  this  regard,  
Choleau et al. demonstrated the effects of the errors in the measurement of capillary blood glucose on 
the accuracy of blood glucose estimations and showed how they depend on the calibration algorithm 
used for blood glucose estimation (one-point versus two points calibration procedure) [60,61]. These 
aspects  should  be  taken  into  account  when  calibrating  CGM  sensors  and  when  the  accuracy  of 
different CGM devices is compared.  
4.2. Principles of Calibration Algorithms in Commercial CGM Devices 
In this section, principles of calibration algorithms implemented in the continuous glucose monitors 
currently on the market are described. All the information contained here has been extracted from 
issued  patents  and  published  patent  applications.  For  an  extensive  review  of  real-time  calibration 
algorithms, filtering and alarms see [62]. 
The first algorithm described here corresponds to the one implemented in the Medtronic CGMS 
Gold [63,64]. The algorithm is intended to estimate blood glucose from raw intensity measured in the 
interstitial fluid in a retrospective way. This is to say, after collecting all the data corresponding to 
three days of operation of the sensor, the algorithm tries to adjust the estimation of blood glucose to 
minimize the absolute relative error of this estimate with respect to the capillary blood glucose in the 
calibration  points.  Once  the  stabilization  process  is  completed,  the  glucose  monitor  measures  the 
continuous  electrical  current  signal  (ISIG)  generated  by  the  glucose  sensor  at  a  sampling  rate  
of 10 seconds. At an interval rate of one minute, highest and lowest values are discarded and the Sensors 2010, 10                                       
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remaining 4 values averaged. Every five minutes, the highest and lowest of those values are ignored 
and the average of the remaining three values is stored. Clipping limits are applied to reduce the effects 
of outliers, transients or extraneous data. Each memory storage value is considered valid unless a 
cancellation event occurs, and the signal is advanced in time two sample periods (10 minutes) to 
account for the physiological lag between plasma and interstitial fluid glucose, i.e., intensity 10 minutes 
ahead (Valid ISIG) is considered for glucose prediction. 
The single point calibration algorithm is based on the assumption that the Valid ISIG will be 0 
when blood glucose is 0. The Single Point Sensitivity Ratio (SPSR) is calculated as the slope of a 
paired calibration point: 
ISIG   Valid
Reading   Reference   Glucose   Blood
SPSR          (3)
 
If SPSR is less than a sensitivity threshold value, then a modified SPSR (MSPSR) is calculated 
using the offset value: 
Offset) ISIG   (Valid
Reading   Reference   Glucose   Blood
MSPSR

         (4)
 
Therefore, the calibrated blood glucose level is: 
MSPSR * Offset) ISIG   (Valid Level   Glucose   Blood        (5) 
Offset value is usually determined empirically. 
When more than one paired data is available, single point calibration is augmented using a modified 
linear regression technique. The linear regression equation is: 
   
    





 N
i i
N
i i i
Offset X
Y Offset X
1
2
1 MLRSR           (6)
 
where Xi is the i-th Valid ISIG of paired calibrations data points, Yi is the i-th Blood Glucose Reference 
Reading of paired calibration data points and N is the total number of paired calibration data points. 
In retrospective algorithms, given a new Valid ISIG, MLRSR is calculated for the data calibrations 
pairs in a window of 24 hours (12 hours before and 12 hours after, including at least three calibration 
data pairs) using several  offset  values  (empirically  chosen). The applied slope corresponds to  the 
MLRSR that minimizes the MAD (Mean Absolute Difference) of the calibrating data pairs within the 
time  window.  Some  refinements  are  included  to  smooth  the  estimation  of  blood  glucose  when  
offset changes.  
The real-time algorithm used by Medtronic [65] is based on the same principle of the retrospective 
one, with  some small  changes.  As  only  data from  previous time instants  are  available, the linear 
regression equation is modified and the linear regression technique described above is executed using 
four paired calibration data points, the most recent and points from 6, 12 and 18 hours prior. Real time 
calibration adjustment is performed to account for changes in the sensor sensitivity during the lifespan 
of  the  glucose  sensor.  In  these  algorithms,  when  a  new  blood  glucose  reference  is  obtained,  a 
calibration factor current (CFc) is calculated (CFc = Meter BG/current ISIG value). The CFc should 
meet some criteria to accept a new current value as accurate ISIG.  Sensors 2010, 10                                       
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In a more robust formula for approximating the slope, more recent ISIGs are given more weight 
than older ones: 


  
   
 i
n i j j
i
n i j j j
i
) 1 (
) 1 (
) (
ISIG   Raw
ISIG   Filtered


        (7)
 
Regarding time lag, the procedure followed in the retrospective case is no longer feasible. In real 
time algorithm, Wiener filters are used to predict values in the future, although no details are given by 
the manufacturer. In a recent patent application [66], other adaptive filters, such as the Kalman filter, 
are proposed for better estimation and prediction of plasma glucose.  
DexCom continuous glucose monitors [67], use a linear least squares regression performed in the 
initial calibration set to create a conversion function. Regression calculates a slope and an offset, which 
defines  the  conversion  function:  y  =  mx  +  b,  where  x-axis  represents  blood  glucose  and  y-axis 
represents sensor data. To account for changes in sensitivity [68], the analyte sensor is provided with 
an auxiliary electrode. For example, the change in sensitivity is measured by measuring a change in 
oxygen concentration, which can be used to provide an independent measurement of the maturation of 
the biointerface, and to indicate when recalibration of the system may be advantageous. 
The auxiliary working electrode can be configured to measure the baseline of the glucose sensor 
over  time.  The  baseline  signal  can  be  subtracted  from  the  glucose  signal  obtained  from  the  
glucose-measuring working electrode to obtain the signal contribution due to glucose only according to 
the following equation: 
Signalglucose only = Signalglucose-measuring working electrode − Signalbaseline-measuring working electrode   (8) 
This  leads  to  a  simplified  calibration  technique,  wherein  variability  in  the  baseline  has  been 
eliminated. Calibration of the resultant differential signal can be performed with a single matched data 
pair by solving the equation y = mx. With regard to time lag compensation, regression techniques are 
used to predict values 15 minutes ahead in time. 
The third continuous glucose monitor currently on the market, Abbott‘s Freestyle Navigator
®, bases 
its basic calibration algorithms on calculating weighted sensitivities [69], as in Medtronic‘s monitors. 
To account for the estimation of sensor sensitivity [70], the analog interface is configured to provide a 
perturbation control signal that affects the sensor response, as an example, changing the voltage level 
that is applied to the sensor between the work and reference electrodes. The sensitivity estimation may 
be determined based on the difference in measured response to different voltage levels according to a 
lookup table. Based on the measured response to the perturbation control signal, the sensor parameters 
are estimated and thus blood glucose level calculated. This procedure can be repeated continuously. A 
method  to  include  lag  compensation  on  the  measured  data  that  is  used  to  update  the  calibration 
parameter  is  also  included  in  the  calibration  algorithms  [71].  To  do  that,  some  filters  (IIR,  FIR, 
Kalman filters, etc.) are used to determine the rate of change of the monitored data at the calibration 
time. Using the glucose rate at time T, the lag corrected sensor data at T-1 can be determined and then 
the  calibration  parameter  updated.  Finally,  the  lag  corrected  calibrated  sensor  data  at  time  T  
is determined. 
In summary,  all the calibration algorithms  implemented in commercially  available home CGM 
devices are based on linear regression techniques. Some differences exist in the strategies adopted for Sensors 2010, 10                                       
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compensation for changes in sensor sensitivity, as well as for lag time. However, regarding the latter 
issue,  not  many  technical  details  are  provided  by  the  manufacturers,  jeopardizing  the  comparison 
between  algorithms.  Main  characteristics  of  current  real-time  calibration  algorithms  are  reported  
in Table 2.  
Table 2. Main characteristics of real-time calibration algorithms. 
  Medtronic  DexCom  Abbott 
Principle  Linear regression  Linear regression  Linear regression 
Sensitivity change 
compensation 
Recalibration when new 
blood glucose is obtained 
so as to minimization of 
MAD 
Measurement of oxygen 
with auxiliary electrode 
and recalibration 
Substraction of sensor 
baseline signal 
Sensitivity estimation 
through application of 
perturbation signals 
(response to different 
potentials) 
Lag compensation  Weiner filter (no details 
provided by the 
manufacturer) 
Linear/nonlinear 
regression used to predict 
values 15 min ahead 
Estimation of glucose 
rate of change through 
filtering 
4.3. Limitations of Current Calibration Strategies and Future Trends in Calibration Algorithms 
Table 3 shows the accuracy reported for the latest monitors from Medtronic, DexCom and Abbott. 
Although no exact implementation of the calibration algorithms is disclosed, it is considered here that 
the principles described in the corresponding patents are followed. It is observed that differences are 
small,  despite  the  differences  in  sensing  technology  and  calibration  algorithms.  A  slightly  better 
accuracy is observed for the Abbott FreeStyle Navigator, which uses wired enzyme technology vs. 
oxygen mediator as in the case of Medtronic and DexCom. However it is not possible to know whether 
this has significance in the achieved accuracy improvement, or whether it is due to the calibration 
algorithm itself. Medtronic Paradigm VEO and DexCom SEVEN Plus have the same mean ARD, 
despite the apparently more sophisticated methodology for the compensation of sensitivity changes by 
DexCom. However, the gold standard used for the calculation of the ARD was different and this may 
bias the results. When compared to a previous monitor by Medtronic, the Guardian REAL-Time, with 
the same gold standard, an improvement of 4% in the mean ARD is achieved by the DexCom algorithm. 
Table 3. Accuracy of latest real-time continuous glucose monitors. 
Continuous glucose monitor  RAD (mean/median)  Gold standard  Source 
Abbott FreeStyle Navigator  12.8%/9.3%  Venous blood (YSI)  [72] 
Medtronic Guardian REAL-Time  19.9%/16.7 %  Venous blood (YSI)  [73] 
Medtronic Paradigm VEO  15.89%/11.56%  Capillary blood (glucometer)  [74] 
Dexcom SEVEN Plus  15.9%/13%  Venous blood (YSI)  [40] 
 
Thus, the calibration algorithm seems to have relatively little impact on a monitor‘s accuracy. One 
explanation is that errors in reference measurements from SMBG, leading to substantial bias in the 
calibrated CGM signal  [42], mask the effect of different calibration algorithms. However, another 
possible reason is that all current algorithms are based on simple linear regression techniques. A static 
relationship between the measured intensity and plasma glucose is considered in this way, neglecting Sensors 2010, 10                                       
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any  plasma-interstitium  transport  dynamics.  In  fact,  usually  the  time  lag  between  plasma  and 
interstitial glucose (and thus to sensor intensity signal) is neglected by the calibration algorithm and 
calibration points are recommended to be taken at ―stationary‖ metabolic states where equilibrium 
between plasma and interstitial glucose is expected [62]. Indeed, recent data demonstrate that the use 
of  dynamic  models  in  the  calibration  algorithm  for  the  estimation  of  plasma  glucose  from  the  
sensor-supplied intensity signal, instead of static linear regression, allows for a significant accuracy 
improvement, even with the use of population  model parameters  [75]. In this  work,  a  population 
autoregressive third order model was tuned from intensity measurements given by a Medtronic CGMS 
Gold monitor and reference plasma glucose measurements (Beckman Glucose Analyzer). Predictions 
given by the model were corrected at every calibration point introduced by the patient. In particular, a 
cross-validation analysis yielded an overall mean ARD of 9.6%, and 8.1% in the hypoglycemic range, 
substantially improving currently reported data of accuracy under hypoglycemic conditions [47]. The 
sensitivity and specificity with respect to hypoglycemia detection were 91.5% and 95%.  
Characterization of the changes in transport dynamics due to the metabolic state may also be of 
special significance. In a recent study by our group (results not yet published) local model techniques 
have revealed the need for different dynamic models (in this case first order linear models) in the 
different  phases  of  a  hypoglycemic  clamp  consisting  of  a  glucose  decrement  to  hypoglycemia,  a 
hypoglycemia  plateau,  and  a  glucose  increment  to  hyperglycemia.  A  mean  ARD  of  7.28%  was 
achieved when compared to gold standard plasma measurements, with 98.46% of glucose estimations 
fulfilling the ISO criteria (15 mg/dL error for glucose values below 75 mg/dL and 20% error otherwise). 
A different approach was adopted by Kuure-Kinsey et al. who used a Kalman filter to improve 
CGM accuracy [76]. In particular, they developed a dual-rate Kalman filter which used the information 
from  both  the  frequent  sensor  measurements  and  the  infrequent  fingerstick  measurements, 
demonstrating  superiority  over  the  one-point  calibration  method.  However,  this  algorithm  still 
neglected  the  blood  glucose  to  interstitial  glucose  kinetics.  The  latter  was  considered  by  
Knobbe  et  al.  [77]  who  developed  a  five-state  extended  Kalman  filter  for  the  estimation  of 
subcutaneous glucose levels, blood glucose levels, time lag between the sensor measured subcutaneous 
glucose and the blood glucose, time-rate-of-change of blood glucose level, and subcutaneous glucose 
sensor  scale  factor.  Its  performance  was  tested  with  data  from  four  patients  with  diabetes, 
demonstrating the potential of this methodology to improve CGM accuracy. Facchinetti et al. further 
developed the strategy proposed by Knobbe et al. and proposed an ‗enhanced Bayesian calibration 
method  (BCM)‘  [78]  based  on  an  extended  Kalman  filter  estimating  interstitial  glucose,  plasma 
glucose  and  sensor  sensitivity  along  time.  A  second  order  random  walk  model  was  proposed  for 
describing plasma glucose; plasma-to-interstitial glucose relationship was described by a first order 
linear differential equation; and sensor sensitivity function was considered to be a triple integration of 
a zero-mean white noise. The method is intended to be used in cascade to any calibration algorithm 
built in commercial CGM, enhancing the monitor output for accuracy improvement. The method was 
validated on simulated data representative of diabetic subjects, and showed improved CGM accuracy 
as compared to the method of Knobbe et al. [77]. However, a drawback of this validation is the use of 
the same model of interstitial glucose and sensor sensitivity for data generation and state estimation, 
although in the first case a robustness analysis considering discrepancies in lag time estimation is 
conducted. Furthermore, as the authors acknowledge, application of the BCM to real data has two Sensors 2010, 10                                       
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main  limitations:  first,  it  requires  the  knowledge  of  the  variances  of  both  state  and  measurement 
processes,  which  in  real-life  conditions  are  unknown;  second,  the  existence  of  a  burn-in  period, 
considered as one day by the authors.  
In  summary,  results  from  studies  exploring  new  calibration  strategies,  suggest  that  the  main 
limitation in current calibration algorithms may be linear regression. Unfortunately, complexity of the 
above mentioned methodologies [76-78] and the lack of its validation in a clinical context with data 
from  prospective,  controlled,  randomized  studies  in  diabetic  subjects,  do  not  still  allow  for  their 
implementation  in  existing  CGM  devices.  However,  whatever  the  method  used,  it  seems  that 
consideration of dynamics of the physiological processes involved in glucose metabolism/kinetics may 
lead in the future to more accurate monitors.  
5. Conclusions  
Despite the huge amount of research in the field of CGM in the last 30 years, accuracy of devices 
currently  available  on  the  market  is  still  suboptimal.  Indeed,  the  final  objective  of  technological 
research  in  diabetes  is  closed  loop  glycemic  control.  The  complexity  of  building  up  an  artificial 
pancreas system requires great quality of the input signal provided to the controller, i.e., the continuous 
glucose registry. Improper calibration technique by the patient has been regarded as a major factor 
contributing to CGM inaccuracy. However, it is our opinion that refining CGM calibration algorithms 
is a priority of any artificial pancreas project. Indeed, linear regression methods do not permit full 
compensation  of  plasma-to-interstitium  discrepancies  during  rapid  changes  in  plasma  glucose 
concentration and often result into erroneous predictions, especially in the hypoglycemic range. Better 
definition of the plasma to interstitial glucose dynamics is needed, under different metabolic conditions 
representative of the daily life of diabetic subjects. Inclusion of this information into new calibration 
algorithms has the potential for substantial improvement of CGM accuracy.  
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